- Experic has appointed Matthew Mollan, Ph.D., as Chief Executive Officer, succeeding David Wood, who is retiring after five years in the role.
- The company reported more than threefold revenue growth since 2021 and expanded from a single U.S. facility to a global organization during Wood’s tenure.
Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services provider, has appointed Matthew Mollan, Ph.D., as Chief Executive Officer. He succeeds David Wood, who will retire after five years leading the company.
Dr. Mollan joins Experic with more than three decades of experience in pharmaceutical development and manufacturing organizations. Most recently, he served as Vice President, Operations, Early Phase at Catalent, where he managed a four-site development and small-scale commercial manufacturing network in the U.S. and UK. During his tenure at Catalent, he supported the development and commercialization of 20 prescription products from Phase I through Phase III without regulatory or quality issues and led multiple facility expansions and capability enhancements.
“I am honored to join Experic at such an exciting stage of its growth. The company has built a strong reputation for quality, flexibility, and partnership. I look forward to working with the talented Experic team to expand on our capabilities, deepen client relationships, and help our customers bring critical therapies to patients efficiently and reliably.”
Dr. Mollan
During Wood’s leadership, Experic expanded from a single U.S.-based facility to a global organization, including the establishment of a clinical trial supply depot in Kilbeggan, Ireland. The company also achieved more than threefold revenue growth since 2021. The business operates as a drug product CDMO and clinical trials supply partner, providing contract manufacturing and integrated services to biopharmaceutical companies.
The Board of Experic stated that Wood played an instrumental role in establishing the company’s integrated model and positioning it for continued growth as it enters its next phase under new leadership.
